Objective To study the relationships between serum IL-18 and IL-18BP and the development,metastasis,curative effect and prognosis of primary liver cancer.Methods There were total 49 cases patients,of which 28 cases primary hepaticcarcinoma(PHC)and 21 cases liver cirrhosis(LC),and 18 cases heathy people.Their serum levels of IL-18 and IL-18BP were determined by using an ELISA assay and comparation.Results The serum IL-18 in PHC was significantly lower than that in LC and controls;the serum IL-18BP in PHC was significantly higher than that in LC and controls;the IL-18 and IL-18BP in LC were significantly higher than those in controls(P

SOX7 belongs to the SOX gene family.And it has been shown to regulate multiple biological processes.Studies have found that SOX7 gene is likely to be a tumor suppressor gene.In many tumors,SOX7 downregulation that inhibits proliferation,migration and invation of tumor via regulating the Wnt-β-catenin signaling pathway mediated the transcription process,which plays a significant role in tumorigenesis.

Studies show that some Trim family proteins are associated with tumorigenesis and cancer progression.Trim members are differently expressed in various cancers including lung cancer,hepatocellular carcinoma,colon cancer,stomach cancer and breast cancer.Trim proteins are found to be involved in tumor progess by modulating the expression of tumor associated genes via several signaling pathways such as p53 and NF-κB pathway.Members of Trim family can be used as oncogenes or anti-oncogenes in the biological processes such as tumor cell proliferation,cell differentiation,cell apoptosis and metastasis.

Objective To evaluate the clinical efficacy,overall survival and toxicities in the patients with advanced non-small cell lung cancer treated by liposome paclitaxel combined with nedaplatin as first-line treating.Methods 34 cases with advanced NSCLC were treated with liposome paclitaxel 150 mg/m2 on day 1 and nedaplatin 80 mg/m2 on day 1 by intravenous infusion,with 21 days as one cycle.The patients were treated with chemotherapy more than 2 cycles.Efficacy evaluation and adverse events were evaluated every 2 cycles.Results 34 patients were available for evaluation of efficacy and adverse events.The patients recieved 174 cycles of chemotherapy,and the median was 5.3 cycles.The objective response rate of liposome paclitaxel combined with nedaplatin was 32.3 ％,the disease control rate was 67.6 ％,the median overall survival was 9.5 months (95 ％ CI 6.2-10.7),1 years survival rate was 40.6 ％.The main adverse events were hematological and gastrointestinal toxicities.Frequent grade Ⅲ-Ⅳ toxicities included neutropenia (41.7 ％),anemia (17.6 ％),thrombocytopenia (8.8 ％),nausea and vomiting (8.8 ％),diarrhea (5.8 ％).Conclusions The regimen of liposome paclitaxel combined with nedaplatin is against advanced non-small cell lung cancer with high efficacy and acceptable toxicities,and it may be used as a new choice for treatment of advanced non-small cell lung cancer.

Objective To study the antitumor effects in vitro and impact on colon cancer in rats of endostatin transfected bifidobacterium oral powder preparation(ETB-2).Methods Growth inhibitory effect of the cecropins on normal human gastric epithelial cell line(GES-1) and human colon adenocarcinoma cell line(LS-174T) was observed using a microculturetetrazolium(MTT) colorimetric methods.Male Wistar rats were divided into 4 groups.All treatments were completed in a course of 18 weeks and the experiment was finished at week 33.Results The cecropins showed selective cytotoxic activity against the human colon adenocarcinoma cell line.There was a significant lower in incidence of colon tumors in rats(70%vs100%,P0.05).Conclusion ETB-2 has significant preventive effect on colon cancer induced by DMH in rats.

Objective To discuss the curative effects and side-effects of combining low-dose domestic interferon(sainuojin)with CHOPP-regimen in treating skin T-lymphoma.Method During the period June 1996 to June 2008,46 cases patient with skin T-lymphoma were treated by low-dose domestic interferon(sainuojin)and CHOPP-regimen,and all patient were received four cycle chemotherapy at least.And the usage was as follows:Sainuojin 3?106U/d,im,d1～21;CTX 600mg/m2,iv,d1;ADM 50mg/m2,iv,d1;VCR 1.4mg/m2,iv,d1;Predinisone 90 mg/d,PO,d1～5;PYM 8mg/d,im,d1,3,5,and every 3 weeks repeat.At the same time,the place of skin lesion was daubed with hydrochloric acid nitrogen mustard once everyday.Results CR 23 cases,PR 16 cases,NC 7 cases.The effective rate was 84.78%.The maximum time of survivorship was 11.6 years;the average survivorship time was 8.9?0.56 years;and the mostly side-effects were arrest of bone marrow and fever.Conclusion The curative effects of combining low-dose domestic interferon(sainuojin)with CHOPP-regimen in treating skin T-lymphoma were confirmed,and the side-effects were small.It is good for clinical popularization and application.

Background and purpose:The effect of TPF (docetaxel, cisplatin and 5-lfuorouracil) induction chemotherapy plus concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma is unclear. This study aimed to compare the outcomes and tolerance of neoadjuvant chemotherapy with TPF versus cisplatin and 5-lfuorouracil (PF) followed by concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma patients.Methods:Patients with locoregionally advanced nasopharyngeal carcinoma were randomly divided into 2 groups: Group TPF and Group PF. Group TPF: One hundred and sixteen nasopharyngeal carcinoma patients received TPF consisting of docetaxel at 60 mg/m2 on day 1, cisplatin at 60 mg/m2 on day 1, and 5-lfuorouracil at a dose of 750 mg/m2by 24 h continuous infusion for 5 days for 3 cycles with a 21 day interval; Group PF: One hundred and sixteen nasopharyngeal carcinoma patients received PF consisting of cisplatin at 80 mg/m2 on day 1, and 5-lfuorouracil at a dose of 750 mg/m2by 24 h continuous infusion for 5 days for 3 cycles with a 21 day interval. After the completion of neoadjuvant chemotherapy, all the patients received intensity modulated radiation therapy (IMRT) with concomitant chemotherapy consisting of 2 cycles of cisplatin at 80 mg/m2 on day 1 and day 22. The prescribed doses were 6 810 cGy at 2.27 Gy/fraction to the gross tumor volume (GTV) with 5 daily fractions per week for 6 weeks. The acute toxicity and tumor response rate (RR), including complete response (CR) and partial response (PR), were evaluated. Addition-ally, the 5-year progress-free survival (PFS) rates and overall survival (OS) rates were further evaluated.Results:RR of Group TPF was higher than that of group PF at the end of neoadjuvant chemotherapy and within 13 weeks of the completion of concurrent chemoradiotherapy. The median recurrence time of TPF group was 2.98 years, and the 5-year PFS was 84.48%. The median recurrence time of PF group was 2.32 years, and the 5-year PFS was 82.75%. There was no statistically signiifcant difference between the 2 groups (P=0.458). The 5-year OS of TPF group was 87.06%, and for the PF group was 85.34%. There was no statistically signiifcant difference between the 2 groups (P=0.274). The incidence of leukopenia, thrombocyte penia, liver and kidney damage, diarrhea and mucosa necrosis in TPF group were signiifcantly higher than those in PF group (P<0.001). TheⅢ andⅣ degrees adverse reactions in TPF group were sig-niifcantly higher than those in PF group (P<0.001).Conclusion:TPF induction chemotherapy was not superior to the PF regimen for locoregionally advanced nasopharyngeal carcinoma patients. It should not be recommended in terms of more acute toxicity.

Background and objective Amorphigenin, a rotenoid compouns, from seeds of Amorpha fruticosa, has been shown to possess anti-proliferation activities in several cancer cells. To explore the antitumor effects of amorphigenin on cisplatin-resistant human lung adenocarcinoma A549/DDP cells and explore the underlying mechanisms.Methods CCK-8 assay was used to measure the proliferation of A549/DDP cells; Colony formation assay was used to measure the colony formation of A549/DDP cells; Flow cytometry assay was used to detect the apoptosis rates; Western blot analysis was used to explore the expression of apoptosis-related proteins (caspase-3 protein, PARP protein) and lung resistance protein (LRP). Results Our results demonstrated that amorphigenin could inhibit the proliferation of A549/DDP cells with a inhibition con-centration of 50% cell growth (IC50) at 48 h of (2.19±0.92) μmol/L. Amorphigenin could inhibit the colony formation ability and induce apoptosis of A549/DDP cells; Furthermore, amorphigenin combined with cisplatin showed synergistic prolifera-tion-inhibitory effect and apoptosis-promoting effect in A549/DDP cells; reduced the expression of LRP of A549/DDP cells. Conclusion Amorphigenin remarkably inhibits the proliferation and induces apoptosis in A549/DDP cells. Combination of amorphigenin with cisplatin had the synergistic inhibitory effect on A549/DDP cells by downregulating the expression of LRP.